Press

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Feb 17 • 6 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial results for its third quarter ended December 31, 2022, and recent business highlights. “Looking ahead, we remain well-positioned to deliver on multiple near-term clinical milestones and data catalysts across our pipeline programs. With interim data expected imminently…

FSD Pharma Inc. Receives Confirmation of NASDAQ Compliance

Feb 17 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it…

FSD Pharma Inc. Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

Feb 17 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse….

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

Feb 17 • 3 min read

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics…

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 17 • 4 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors of David Weiner, MD, as a non-executive director. The appointment is effective immediately. “I am delighted to welcome David to the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435